(3.238.130.97) 您好!臺灣時間:2021/05/13 23:24
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:劉玉晴
研究生(外文):Yu-Ching Liu
論文名稱:合成FIT-OH及AVLPR-OH類緣化合物作為細胞分化劑與有絲分裂抑制劑
論文名稱(外文):Synthesis of FIT-OH and AVLPR-OH analogs as cell differentiation agents and antimitotic agents
指導教授:郭盛助郭盛助引用關係黃麗嬌黃麗嬌引用關係
指導教授(外文):Sheng-Chu KuoLi-Jiau Huang
學位類別:碩士
校院名稱:中國醫藥學院
系所名稱:藥物化學研究所
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2001
畢業學年度:89
語文別:中文
論文頁數:79
中文關鍵詞:細胞分化劑有絲分裂抑制劑固相peptide合成分子模擬
外文關鍵詞:cell differentiation agentsantimitotic agentsSolid Phase Peptide SynthesisMolecular Modeling
相關次數:
  • 被引用被引用:0
  • 點閱點閱:190
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
延續針對更強的細胞分化劑之研究中,選擇以AVLPR-OH為先導化合物做結構上的修飾。另一方面,由分子模擬設計一系列FIT-OH類緣化合物做為有絲分裂抑制劑。
標的化合物的合成以標準的固相peptide合成方法,針對peptide acids (TP-1, TP-3~TP-11及PP-1)之合成用Fmoc-Amino acid-Wang resin,而對於peptide amides (TP-2, PP-2及PP-3)之合成用Rink resin;合成之產物由逆相-高效液相層析法純化,繼而分子量由FAB-MS確認。

As part of our continuing search for potential cell differentiation agents, AVLPR-OH was selected as the lead compound for structural modification. On the other hand, a series of FIT-OH analogs was designed as antimitotic agents by Molecular Modeling.
The target compounds were synthesized on Fmoc-Amino acid-Wang resin for peptide acids (TP-1, TP-3 — TP-11 and PP-1), and Rink resin for peptide amides (TP-2, PP-2 and PP- 3), by standard Solid Phase Peptide Synthesis. Each of synthesized products were purified by RP-HPLC and their molecular weight were confirmed by FAB-MS.

目錄
中文摘要..................................................1
英文摘要..................................................2
第一章 緒論..............................................3
第一節 細胞分化療法......................................4
第二節 抗有絲分裂活性(Antimitotic activity)..............7
第三節 Peptide固相合成法(Solid-phase peptide synthesis;
SPPS)之簡介.......................................10
第二章 研究的動機與目的.................................18
第三章 結果與討論
第一節 化學合成..........................................23
第二節 生理活性..........................................32
第四章 結論..............................................33
第五章 實驗部分
第一節 試藥與重要儀器..................................34
第二節 合成方法........................................37
附表
Table 1..................................................50
Table 2..................................................51
參考文獻.................................................53
附圖.....................................................59

參考文獻
1.韓銳 腫瘤化學預防及藥物治療. 北京醫科大學 中國協禾醫科, 大
學聯合出版社 1991.
2.Pierce, G. B.; Dixon, F. J.; Verney, E. L. Teratocarcinogenic
and tissue forming potentials of the cell types comprising
neoplastic embryoid bodies. Lab. Invest. 1960, 9, 583-602.
3.Collins, S. J.; Ruscetti, F. W.; Gallagher, R. E.; Gallo, R.
C. Terminal differentiation of human promyelocytic leukemia
cells induced by dimethyl sulfoxide and other polar
compounds. Proc. Natl. Acad. Sci. 1978, USA 75(5), 2458-2462.
4.Dexter, D. L.; Hager, J. C. Maturation-induction of tumor
cells using a human colon carcinoma model. Cancer. 1980, 45(5
Suppl), 1178-1184.
5.Breitman, T. R.; Selonick, S. E.; Collins, S. J. Induction of
differentiation of the human promyelocytic leukemia cell line
(HL-60) by retinoic acid. Proc. Natl. Acad. Sci. 1980, USA 77
(5), 2936-2940.
6.Chen, Z. X.; Xue, Y. Q.; Zhang, R.; Tao, R. F.; Xia, X. M.;
Li, C.; Wang, W.; Zu, W. Y.; Yao, X. Z.; Ling, B. J. A
clinical and experimental study on all-trans retinoic acid-
treated acute promyelocytic leukemia patients. Blood. 1991, 78
(6), 1413-1419.
7.Huang, M. E.; Ye, Y. C.; Chen, S. R.; Chai, J. R.; Lu, J. X.;
Zhoa, L.; Gu, L. J.; Wang, Z. Y. Use of all-trans retinoic
acid in the treatment of acute promyelocytic leukemia. Blood.
1988, 72(2), 567-572.
8.Liau, M. C.; Liau, C. P.; Burzynski, S. R. Potentiation of
induced terminal differentiation by phenylacetic acid and
related chemicals. Intl. J. Exptl. Clin. Chemother. 1992, 5,
9-17.
9.Liau, M. C.; Burzynski, S. R. Riboflavin as a minor active
anticancer component of antineoplaston A2 and A5. Intl. J.
Tiss. React. 1990, 12 (suppl.), 19.
10.Liau, M. C.; Huang, L. J.; Lee, J. H.; Chen, S. C.; Kuo, S.
C. Development of helper inducers to take part in the
differentiation therapy of cancer. Chin. Pharm. 1998, 50,
289-303.
11.Frankel, S. R.; Eardley, A.; Lawers, G.; Weiss, M.; Warrell,
R. P. The “retinoic acid syndrom” in acute promyelocytic
leukemia. Ann. Intern. Med. 1992, 117(4), 292-296.
12.Burzynski, S. R. Antineoplastons. : biochemical defense
against cancer. Physiol. Chem. Phys. 1976, 8(3), 257.
13.Burzynski, S. R. Treatment of malignant brain tumors with
antineoplaston. Adv. Exptl. Clin. Chemother. 1988, 6/88, 45-
46.
14.Lee, S. S.; Burzynski, S. R. Tissue culture and aminal
toxicity studies of Antineoplaston A5. Drug Exptl. Clin.
Res. 1987, I (suppl.) XIII, 37-43.
15.Wordenmam, L.; mitchison, T. J. Dynamics of microtubule
assembly in vivo. In Microtubules; Hyams, J. S.; Lloyd, C.
W., Eds.; Wiley-Liss, Inc.: New York, 1994, P287-301.
16.Rowinsky, E. K.; Donehower, R. C. The clinical pharmacology
and use of antimicrotubule agents in cancer
chemotherapeutics. [Review] [643 refs] Pharmacology &
Therapeutics. 1991, 52(1), 35-84.
17.Verweij, J.; Clavel, M.; Chevalier, B. Paclitaxel (Taxol)
and docetaxel (Taxotere): not simply two of a kind. [Review]
[115 refs] Annals of Oncology. 1994, 5(6), 495-505.
18.Hastie, S. B. Interactions of colchicine with tubulin.
[Review] [182 refs] Pharmacology & Therapeutics. 1991, 51
(3), 377-401.
19.Brossi, A.; Yeh, H. J.; Chrzanowska, M.; Wolff, J.; Hamel,
E.; Lin, C. M.; Quinn, F.; Suffness, M.; Silverton, J.
Colchicine and its analogues: recent findings. Med. Res.
Rev. 1988, 8(1), 77-94.
20.Hamel, E.; Lin, C. M.; Plowman, J.; Wang, H. K.; Lee, K. H.;
Paul, K. D. Antitumor 2,3-dihydro-2-(aryl)-4-(1H)-
quinazolinone derivatives. Interactions with tubulin.
Biochem. Pharmacol. 1996, 51, 53-59.
21.Hamel, E.; Ho, H. H.; Kang, G. J.; Lin, C. M. Cornigerine, a
potent antimitotic colchicum alkaloid of unusual structure:
interactions with tubulin. Biochem. Pharmacol. 1988, 37(12),
2445-2449.
22.Kelly, M.; Hartwell, J. The biological effects and the
chemical composition of podophyllin. J. Natl. Cancer Inst.
1954, 14, 967-1010.
23.Cortese, F.; Bhatta Charyya, B.; Wolff, J. Podophyllotoxin
as a probe for the colchicine binding site of tubulin. J.
Biol. Chem. 1977, 252(4), 1134-1140.
24.Wang, R. W. J.; Rebhun, L. I.; Kupchan, S. M. Antimitotic
and antitubulin activity of tumor inhibitor steganacin.
Cancer Res. 1977, 37(9), 3071-3079.
25.Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic
natural products combretastatin A-4 and combretastatin A-2:
studies on the mechanism of their inhibition of the binding
of colchicine to tubulin. Biochemistry. 1989, 28(17), 6984-
6991.
26.Xia, Y.; Yang, Z. Y.; Xia, P.; Bastow, K. F.; Taxhibana, Y.;
Kuo, S. C.; Hamel, E.; Hackl, T.; Lee, K. H. Antitumor
agents. 181. Synthesis and biological evaluation of
6,7,2',3',4'-substituted -1,2,3,4-tetrahydro
-2-phenyl-4-quinolones as a new class of antitmitotic
antitmor agents. J. Med. Chem. 1998, 41(7), 1155-1162.
27.Kuo, S. C.; Lee, H. Z.; Juang, J. P.; Lin, Y. T.; Wu, T. S.;
Chang, J. J.; Dan lednicer; Kenneth, D. Paul; Lin, C. M.;
Ernest Hamel; Lee, K. H. Synthesis and cytotoxicity of
1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones
and related compounds: Identification as Antimitotic agents
interacting with tubulin. J. Med. Chem. 1993, 36(9), 1146-
1156.
28.Li, L.; Wang, H. K.; Kuo, S. C.; Wu, T. S.; Lendnicer, D.;
Lin, C. M.; Hamel, E.; Lee, K. H. Antitumor agents. 150.
2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and
related compounds: their synthesis, cytotoxicity, and
inhibition of tubulin polymerization. J. Med. Chem. 1994, 37
(8), 1126-1135.
29.Li, L.; Wang, H. K.; Kuo, S. C.; Wu, T. S.; Mauger, A. A.;
Lin, C. M.; Hamel, E.; Lee, K. H. Antitumor agents. 155.
Synthesis and biological evaluation of 3',6,7- substituted 2-
phenyl-4-quinolones as microtubule agents. J. Med. Chem.
1994, 37(8), 3400-3407.
30.Neil, G. L.; Li, L. H.; Buskirk, H. H.; Moxley, T. E.
Antitumor effects of the antispermatogenic agent, 2,3-
dihydro-2-(1-naphthyl)-4-
(1H)-quinazolinone. Cancer Chemother. 1972, 56(2), 163-173.
31.Yale,H. J.; Kalkstein, M. Substituted 2,3-dihydro-4-(1H)-
quinazolinones. A new class of inhibitors of cell
multiplication. J. Med. Chem. 1967, 10, 334-336.
32.du Vigneaud, V.; Ressler, C.; Swan, J. M.; Roberts, C. W.;
Katsoyannis, P. G.; Gordon, S. The synthesis of a peptide
with the hormonal activity of oxytocin. J. Am. Chem. Soc.
1953, 75, 4879-4880.
33.Bodanszky, M.; Williams, N. J. Synthesis of secretin. I. The
protected tetradecapeptide corresponding to sequence 14-27.
J. Am. Chem. Soc. 1967, 89(3), 685-689.
34.Sieber, P.; Brugger, M.; Kamber, B.; Riniker, B.; Rittel, W.
[Human calcitonin. IV. Synthesis of calcitonin M]. [German]
Helvetica Chimica Acta. 1968, 51(8), 2057-2061.
35.Haruaki, Y.; Yoshio, Yoshiaki, K. Stratgy and Tactics for
Peptide Synthesis. Hirokawa. Co., Tokyo, Japan. 1990, P279-
281.
36.Merrifield, R. B. Solid phase peptide synthesis I. The
synthesis of a tetrapeptide. J. Am. Chem. Soc. 1963, 85,
2149-2154.
37.Haruaki, Y.; Yoshio, Yoshiaki, K. Stratgy and tactics for
peptide synthesis. Hirokawa. Co., Tokyo, Japan. 1990, P308-
311.
38.Kent, S. B. H.; Mitchell, H. R.; Engehard, M.; Merrifield,
R. B. Synthesis of the Thf moiety of Annonacin based on
Aldolisation and Baeyer-Villiger oxidation. Proc. Natl.
Acad. Sci. 1979, USA 76, 2180-2184.
39.Jornvall, H. Blocked alpha-amino groups in peptides due to
diketopiperazine formation. FEBS Letters. 1974, 38(3), 329-
333.
40.Bray, A. M.; Maeji, N. J.; Geysen, H. M. Synthesis of a
peptide-linked binuclear Platinum (II)-terpyridine complex.
Tetrahedron Lett. 1990, 31, 5811-5814.
41.Wu, C. R.; Wade, J. D.; Tregear, G. W. Beta-subunit of
Baboon Chorionic Gonadotropin continuous flow Fmoc-polyamide
synthesis of the C-terminal 37-peptide. Int. J. Peptide
Protein Res. 1988, 31(1), 47-57.
42.Konig, W.; Geiger, R. A New amide protecting group. Chem.
Ber. 1970, 103(7), 2041-2051.
43.Marglin, A.; Merrifield, R. B. The synthesis of bovine
Insulin by the solid phase method. J. Am. Chem. Soc. 1966, 88
(21), 5051-5052.
44.Hancock, W. S.; Prescott, D. J.; Marshall, G. R.; Vagelos,
P. R. Acyl carrier protein 28. Chemical synthesis and
characterization of a protein with acyl carrier protein
activity. J. Biol. Chem. 1972, 247(19), 6224-6233.
45.Sharp, J. J.; Robinson, A. B.; Kamen, M. D. Synthesis of a
polypeptide with lysozyme activity. J. Am. Chem. Soc. 1973,
95(18), 6097-6108.
46.Yasuhito, T.; Hiroshi, T.; Yuji, M.; Masayuki, I.; Tadashi,
K.; Masaya, U. M.; Takehito, I.; Miyuki, T.; Muneo, Y.;
Seiichi, S.; Yukihito, I.; Keiya, O.; Kiyohiko, H. NH2-
terminal pentapeptide of endothelial interleukin 8 is
responsible for the induction of apoptosis in leukemic cells
and has an antitumor effect. Cancer Res. 1999, 59(22), 5651-
5655.
47.Monica, D.; Stefano, P.; Paolo, R.; Silvio, B.; Andrea, B.;
Carlo, D. B. SPPS of difficult sequences. A comparison of
chemical conditions, synthetic strategies and on-line
monitoring. J. Peptide Res. 1997, 49(1), 103-111.

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔